Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

A law signed in 2023 caps out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors beginning Jan. 1.

Gerich, MD; Hertzel C. Gerstein, MD, MSC Inhaled insulin was associated with a lower overall hypoglycemia rate but higher severe hypoglycemia rate. As described in the online appendix, four ...

A brand new law will bring financial relief to hundreds of thousands of Minnesotans dealing with diabetes and asthma. The law ...

An “inhaled insulin” is set to join the repertoire of options available to people with diabetes, as drugmaker Cipla completes last mile procedures to import Afrezza from US’ MannKind ...

“Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, according to a study published online Dec.

MNKD’s portfolio in the endocrine area includes Afrezza, an insulin human inhalation powder for adults with diabetes mellitus type 2 [T2D]. Currently, Afrezza is marketed in the US and ...